ChromaCode, a Carlsbad, CA-based genomics multiplexing platform company developing accessible and affordable solutions for laboratories, patients and physicians, received a strategic investment from corporate venture capital fund Shimadzu Future Innovation Fund L.P., with general partner Global Brain Corporation.
The amount of the deal was not disclosed.
This funding will support ChromaCode’s continued development of its HDPCR technology to deliver diagnostic tools that address unmet clinical needs in disease detection and monitoring.
Led by CEO Mark McDonough, ChromaCode is an innovator in molecular genomics, driving integration from labs to physicians to patients and connecting them to the right treatment through its proven HDPCR™ multiplexing platform. This technology expands the accessibility of genomic and oncology diagnostic applications in patient communities with a cost effective and scalable dPCR-based solution compatible with existing instrumentation and using standard workflows.
FinSMEs
07/07/2023